Detalhe da pesquisa
1.
A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
N Engl J Med
; 387(25): 2331-2343, 2022 12 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36546625
2.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Lancet Respir Med
; 12(2): 117-128, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-37980911
3.
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.
PLOS Glob Public Health
; 2(12): e0001337, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36962909
4.
TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
Trials
; 23(1): 484, 2022 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35698158
5.
Optimising recruitment to a late-phase tuberculosis clinical trial: a qualitative study exploring patient and practitioner experiences in Uzbekistan.
Trials
; 22(1): 881, 2021 Dec 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863253